Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|MV-NIS||NSC-731414|NSC731414||MV-NIS is a oncolytic strain of measles virus that expresses human sodium iodide symporter, which may increase anti-tumor immune response (PMID: 25398436, PMID: 22185260, PMID: 28439108).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||multiple myeloma||not applicable||MV-NIS||Phase Ib/II||Actionable||In a Phase I/II trial, MV-NIS treatment resulted in enhanced T-cell response to tumor antigens in 40% (4/10) of patients with multiple myeloma (Journal of Clinical Oncology 36, no. 5_suppl (February 10 2018) 218-218; NCT00450814).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02068794||Phase Ib/II||MV-NIS||MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian Cancer||Recruiting|
|NCT02364713||Phase II||Pegylated liposomal-doxorubicin Bevacizumab + Topotecan Topotecan Paclitaxel MV-NIS Bevacizumab + Paclitaxel Bevacizumab + Pegylated liposomal-doxorubicin Gemcitabine||MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer||Recruiting|
|NCT03171493||Phase I||MV-NIS||Trial of Intravesical Measles Virotherapy in Patients With Bladder Cancer Who Are Undergoing Radical Cystectomy||Recruiting|
|NCT02192775||Phase II||MV-NIS||UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus||Completed|
|NCT02700230||Phase I||MV-NIS||Vaccine Therapy in Treating Patients With Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery||Recruiting|